Cargando…

Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges

Cell therapy has proven to be a burgeoning field of investigation, evidenced by hundreds of clinical trials being conducted worldwide across a variety of cell types and indications. Many cell therapies have been shown to be efficacious in humans, such as modified T-cells and natural killer (NK) cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iyer, Rohin K., Bowles, Paul A., Kim, Howard, Dulgar-Tulloch, Aaron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974219/ https://www.ncbi.nlm.nih.gov/pubmed/29876351 http://dx.doi.org/10.3389/fmed.2018.00150

Ejemplares similares

Commercial Scale Manufacturing of Allogeneic Cell Therapy
por: Pigeau, Gary M., et al.
Publicado: (2018)

Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies
por: Ganeeva, Irina, et al.
Publicado: (2022)

Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges
por: Luzzi, Sabino, et al.
Publicado: (2020)

Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy
por: Fernández, Adrián, et al.
Publicado: (2021)

Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer
por: Huang, He, et al.
Publicado: (2022)

Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment
por: Delfanti, Gloria, et al.
Publicado: (2022)

Inducement factor of talent agglomeration in the manufacturing industrial sector: A survey on the readiness of Industry 4.0 adoption
por: Feng, Yanchao
Publicado: (2023)

Recent advances in adoptive cancer immunotherapy in china
por: Zhou, Juhua
Publicado: (2015)

Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial
por: Gao, Yao, et al.
Publicado: (2021)

Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital
por: Hort, Simon, et al.
Publicado: (2022)

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy
por: Yee, Cassian
Publicado: (2005)

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
por: Bonifacius, Agnes, et al.
Publicado: (2023)

Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2016)

Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges
por: Nianias, Alexandros, et al.
Publicado: (2019)

The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy
por: Gardner, Joanne K., et al.
Publicado: (2018)

Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies
por: Kast, Florian, et al.
Publicado: (2021)

Industrial controls and manufacturing
por: Kamen, Edward W
Publicado: (1999)

Challenges for Relative Effectiveness Assessment and Early Access of Cancer Immunotherapies in Europe
por: Pavlovic, Mira
Publicado: (2016)

Good manufacturing practice production of CD34(+) progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia
por: de Jonge, P. K. J. D., et al.
Publicado: (2023)

Immunotherapy: ADOPTIVE T CELL IMMUNOTHERAPY FOR SARS-COV-2
por: Henden, A., et al.
Publicado: (2023)

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
por: Berghmans, Thierry, et al.
Publicado: (2020)

Assessing Advance Care Planning in Individuals with Lynch Syndrome
por: Fenton, Victoria, et al.
Publicado: (2021)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer
por: Karlsson, Mona, et al.
Publicado: (2010)

Industrial, mechanical and manufacturing science
por: Zheng, Dawei
Publicado: (2015)

Recent advances in additive manufacturing of engineering thermoplastics: challenges and opportunities
por: Picard, Maisyn, et al.
Publicado: (2020)

Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations
por: Hong, Guodai, et al.
Publicado: (2019)

The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
por: Abakushina, Elena V., et al.
Publicado: (2021)

Enhancement of Antiviral T-Cell Responses by Vitamin C Suggests New Strategies to Improve Manufacturing of Virus-Specific T Cells for Adoptive Immunotherapy
por: Laubert, Miriam, et al.
Publicado: (2022)

Recent Advances and Future Challenges in the Additive Manufacturing of Hydrogels
por: Danek, Chris
Publicado: (2022)

What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvements
por: Miletic, Nevena, et al.
Publicado: (2023)

Digital adoption and efficiency in the maritime industry
por: Gavalas, Dimitris, et al.
Publicado: (2022)

Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities
por: Hayman, Benoit, et al.
Publicado: (2021)

Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)

Application Of Adoptive Immunotherapy In Ovarian Cancer
por: Yang, Siyu, et al.
Publicado: (2019)

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

Adoptive Immunotherapy and High-Risk Myeloma
por: Duane, Catherine, et al.
Publicado: (2023)

Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021)

Recent Advances and Challenges in Cancer Immunotherapy
por: Peterson, Chelsea, et al.
Publicado: (2022)

More Haste, Less Speed: Could Public–Private Partnerships Advance Cellular Immunotherapies?
por: Bubela, Tania, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2lstd9p809qnhm9svsgqhduvqd